Loading candles…
SMS Lifesciences Ltd, incorporated in 2006 and headquartered in Hyderabad, India, operates in the pharmaceutical industry. The company specializes in the manufacturing of Active Pharmaceutical Ingredients (API) and their intermediates. It was formed following a demerger from SMS Pharmaceuticals Limited. Subsequently, SMS Lifesciences Ltd rebranded to Haleos Labs Ltd, previously known as SMS Lifesciences India Limited, adopting the motto 'Chemistry for Good Health.' The company’s operations are focused within India, and no subsidiaries or listing exchanges are reported.
This page is a live market overview for HALEOS LABS LIMITED (HALEOSLABS) on the NSE. As a listed security, HALEOS LABS LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for HALEOSLABS before placing trades on tick2trade.
As of the latest feed, HALEOSLABS last traded at ₹1,457.4 on NSE, up ₹18.7 (1.30%) from the previous close of ₹1,438.7. Today's session range is ₹1,431.6 – ₹1,469.6, against a 52-week band of ₹1,067 – ₹1,774. Traded volume today stands at 391 shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for HALEOSLABS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether HALEOSLABS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for HALEOS LABS LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in HALEOSLABS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated HALEOSLABS option chain page linked from this overview.
| Results - FY26 |
| To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 29 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 11 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 10 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 11 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters | 29 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.